全文获取类型
收费全文 | 7123篇 |
免费 | 474篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 75篇 |
儿科学 | 205篇 |
妇产科学 | 112篇 |
基础医学 | 1079篇 |
口腔科学 | 142篇 |
临床医学 | 488篇 |
内科学 | 1894篇 |
皮肤病学 | 300篇 |
神经病学 | 570篇 |
特种医学 | 234篇 |
外科学 | 529篇 |
综合类 | 50篇 |
一般理论 | 1篇 |
预防医学 | 465篇 |
眼科学 | 155篇 |
药学 | 525篇 |
中国医学 | 43篇 |
肿瘤学 | 769篇 |
出版年
2024年 | 10篇 |
2023年 | 57篇 |
2022年 | 123篇 |
2021年 | 202篇 |
2020年 | 119篇 |
2019年 | 160篇 |
2018年 | 202篇 |
2017年 | 193篇 |
2016年 | 210篇 |
2015年 | 190篇 |
2014年 | 309篇 |
2013年 | 344篇 |
2012年 | 482篇 |
2011年 | 569篇 |
2010年 | 338篇 |
2009年 | 342篇 |
2008年 | 440篇 |
2007年 | 529篇 |
2006年 | 472篇 |
2005年 | 507篇 |
2004年 | 499篇 |
2003年 | 441篇 |
2002年 | 385篇 |
2001年 | 49篇 |
2000年 | 27篇 |
1999年 | 47篇 |
1998年 | 62篇 |
1997年 | 47篇 |
1996年 | 45篇 |
1995年 | 30篇 |
1994年 | 23篇 |
1993年 | 24篇 |
1992年 | 10篇 |
1991年 | 12篇 |
1990年 | 12篇 |
1989年 | 14篇 |
1988年 | 7篇 |
1987年 | 11篇 |
1986年 | 9篇 |
1985年 | 6篇 |
1984年 | 9篇 |
1983年 | 7篇 |
1982年 | 6篇 |
1981年 | 8篇 |
1980年 | 10篇 |
1978年 | 3篇 |
1977年 | 5篇 |
1975年 | 5篇 |
1974年 | 7篇 |
1972年 | 4篇 |
排序方式: 共有7636条查询结果,搜索用时 15 毫秒
91.
92.
93.
Shunsuke Uno Yosuke Horiuchi Takae Uchida Akiko Yonaha Takanori Miyata Eiko Nagano Takao Kodama Naoki Hasegawa 《Journal of infection and chemotherapy》2018,24(10):849-851
Aggregatibacter actinomycetemcomitans is well-known as the pathogen of gingivitis or periodontitis, and discitis or vertebral osteomyelitis cases caused by this organism have rarely been reported. Ampicillin or amoxicillin has been used in the previously reported discitis cases; however, no cases have been reported that is treated with levofloxacin. We report the first published case we chose levofloxacin to treat. We failed to perform the susceptibility testing because of the poor growth and fastidious nature of the organism, and the result of susceptibility of amoxicillin was unclear. Levofloxacin, which A. actinomycetemcomitans is usually susceptible to, can be an effective alternative oral antimicrobial agent in such cases. 相似文献
94.
Tsubasa Hiraki Miho Hatanaka Akiko Arimura Hisao Kawahira Mari Kirishima Ikumi Kitazono Michiko Horinouchi Michiyo Higashi Takuro Kanekura Akihide Tanimoto 《Journal of cutaneous pathology》2020,47(2):154-160
Nivolumab and pembrolizumab are humanized IgG4 monoclonal antibodies against programmed cell death 1 (PD-1). Although these agents are effective in treating advanced melanoma, non-small-cell lung carcinoma, and other types of cancers, various adverse events have been reported. Cutaneous adverse events are particularly prevalent and, while granulomatous/sarcoid-like reactions are uncommon, they are increasingly recognized as immune-related adverse events associated with immune checkpoint inhibitors. Herein, we report two cases of granulomatous/sarcoid-like reaction with foreign material, mimicking metastatic malignancy after PD-1 inhibitor treatment. Clinicians should be aware of the existence of cutaneous lesions and perform biopsy if needed to prevent misdiagnosis and unnecessary adjustments to immunotherapy. 相似文献
95.
Akihisa Kawajiri Shigehisa Kitano Akiko Miyagi Maeshima Yoshihiro Inamoto Kinuko Tajima Tomonari Takemura Takashi Tanaka Ayumu Ito Keiji Okinaka Saiko Kurosawa Sung‐Won Kim Hirokazu Taniguchi Chitose Ogawa Koji Izutsu Noboru Yamamoto Takahiro Fukuda 《European journal of haematology》2019,103(6):578-587
96.
Sakti Chakrabarti Jaskanwal Sara Ronstan Lobo Rachel Eiring Heidi Finnes Jessica Mitchell Mindy Hartgers Akiko Okano Thorvardur Halfdanarson Axel Grothey 《Clinical colorectal cancer》2019,18(1):52-57
Introduction
Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU. Given the additional benefit of oxaliplatin over FP alone in the management of colorectal cancer, retaining oxaliplatin in the treatment regimen is desirable, but the safety of combining bolus 5-FU with oxaliplatin in patients with FP-induced vasospasm is not well established. We performed a retrospective review to explore the safety of substituting FLOX (bolus 5-FU, oxaliplatin, leucovorin) for FOLFOX (infusional 5-FU, oxaliplatin, leucovorin) and CAPOX (capecitabine, oxaliplatin) in patients who had FP-induced coronary vasospasm.Patients and Methods
The pharmacy database of Mayo Clinic was queried to identify patients who developed coronary vasospasm associated with FOLFOX or CAPOX between January 2011 and January 2018 and were subsequently treated with FLOX. Detailed information was obtained on these patients by retrospective electronic chart review.Results
A total of 10 patients (median age, 56.5 years; range, 36-77 years) were identified, 9 with FOLFOX and 1 with CAPOX. Among the patients treated with FOLFOX, 8 patients had chest pain as the presenting complaint that had started within 48 hours of beginning of the 5-FU infusion. In 9 of 10 patients, coronary vasospasm occurred with the first cycle of therapy. All patients made full recovery after discontinuation of infusional 5-FU or capecitabine. All patients subsequently received FLOX with 7 median bolus 5-FU doses (range, 2-22 doses) and 7 median oxaliplatin doses (range, 2-12 doses) at 7 days to 18 months after the event, with 7 patients treated within 4 weeks of the event. FLOX did not cause any cardiovascular adverse events in any of the 10 patients.Conclusion
Bolus 5-FU in combination with oxaliplatin is safe in patients who have experienced coronary vasospasm with infusional 5-FU or capecitabine. 相似文献97.
98.
Kato Akiko Inagaki Koji Utsumi Michiya Kato Kazuo Honda Masaki 《Odontology / the Society of the Nippon Dental University》2021,109(1):193-200
Odontology - The aim of this study was to investigate root canal configurations in maxillary first and second molars from a Japanese population, as well as the relationship between the root canal... 相似文献
99.
100.
Objective: The purpose of this study was to examine the relationship between
the emotional intelligence quotient and health-related quality of life using structural
equation modeling.Methods: A self-administered questionnaire survey was conducted among 1,911
mothers who visited the Health Center for an infant medical examination. A hypothetical
model was constructed using variables of the emotional intelligence quotient, social
support, coping, parenting stress, and perceived health competence.Result: There were a total of 1,104 valid responses (57.8%). Significant
standardized estimates were obtained, confirming the goodness of fit issues with the
model. The emotional intelligence quotient had a strong impact on physical and
psychological quality of life, and showed the greatest association with coping. This study
differed from previous studies in that, due to the inclusion of social support and
explanatory variables in coping, an increase in coping strategies was more highly
associated with emotional intelligence quotient levels than with social support.Conclusion: An enhanced emotional intelligence quotient should be considered
a primary objective to promote the health of mothers with infant children. 相似文献